By Business Wire, February 21, 2013, 04:05:00 PM EDT
AMSTERDAM--(BUSINESS WIRE)--
Tornier, N.V. (NASDAQ:TRNX), a global medical device company focused on
providing surgical solutions to orthopaedic extremity specialists,
announced today that its Board of Directors has appointed David H. Mowry
as President and Chief Executive Officer, effective immediately.
Sean D. Carney, Chairman of Tornier, commented, "Dave has demonstrated
an intensity and concentration in executing on the key initiatives in
his charge since joining Tornier in July 2011 as Chief Operating
Officer. That expertise, combined with his extensive industry experience
and outstanding leadership qualities, make Dave the right executive to
continue to build Tornier's strong brand and reputation in the
extremities market."
David H. Mowry commented, "Tornier's industry expertise, broad product
portfolio, and cadence of delivering innovation position the Company as
a recognized global leader in the large and growing extremities markets.
We believe the increased focus on execution of our US sales channel
alignment, OrthoHelix integration, and delivering through our strong
product pipeline will return Tornier to double-digit, constant currency
revenue growth on a pro forma basis. I am grateful to the Board of
Directors for the opportunity to lead Tornier, and I am excited to work
with the talented and dedicated Tornier team."
Mr. Mowry joined Tornier N.V. in July 2011 as Chief Operating Officer.
He brings to Tornier 23 years of medical device industry experience in
various engineering and management assignments. Prior to Tornier, Mr.
Mowry served as Senior Vice President and President of the Neurovascular
Division of Covidienplc, and in the same position with ev3 Inc., prior
to its acquisition by Covidien. Before joining ev3, Mr. Mowry served as
Vice President of Operations and Logistics at the Zimmer Spine division
of Zimmer Holdings Inc. Mr. Mowry is a graduate of the United States
Military Academy at West Point, New York with a degree in Engineering
and Mathematics.
About Tornier
Tornier is a global medical device company focused on serving
extremities specialists who treat orthopaedic conditions of the
shoulder, elbow, wrist, hand, ankle and foot. The Company's broad
offering of over 100 product lines includes joint replacement, trauma,
sports medicine, and ortho-biologic products through Tornier and
OrthoHelix brands to treat the extremities, as well as joint replacement
products for the hip and knee in certain international markets. Since
its founding approximately 70 years ago, Tornier's "Specialists Serving
Specialists" philosophy has fostered a tradition of innovation, intense
focus on surgeon education, and commitment to advancement of orthopaedic
technology stemming from its close collaboration with orthopaedic
surgeons and thought leaders throughout the world. For more information
regarding Tornier, visit www.tornier.com,
or OrthoHelix, visit www.orthohelix.com.
Forward-Looking Statements
Statements contained in this release that relate to future, not past,
events are forward-looking statements under the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based on
current expectations of future events and often can be identified by
words such as "believe," expect," "should," "project," "anticipate,"
"intend," "will," "may," "could," "would," "continue," "future," other
words of similar meaning or the use of future dates. Examples of
forward-looking statements in this release include Tornier's return to
double-digit constant currency revenue growth. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Uncertainties and risks may cause Tornier's actual
results to be materially different than those expressed in or implied by
Tornier's forward-looking statements. For Tornier, such uncertainties
and risks include, among others, Tornier's future operating results and
financial performance, fluctuations in foreign currency exchange rates,
the effect of global economic conditions, the European sovereign debt
crisis, and austerity measures, risks associated with Tornier's
international operations and expansion, risks associated with Tornier's
recent acquisition of OrthoHelix and the new credit facility agreement,
the timing of regulatory approvals and introduction of new products,
physician acceptance, endorsement, and use of new products; the effect
of regulatory actions, changes in and adoption of reimbursement rates,
potential product recalls, competitor activities, the effect of changes
in Tornier's distribution channels and the costs and effects of
litigation and changes in tax and other legislation. More detailed
information on these and other factors that could affect Tornier's
actual results are described in Tornier's filings with the U.S.
Securities and Exchange Commission, including its most recent annual
report on Form 10-K and subsequent quarterly reports on Form 10-Q.
Tornier undertakes no obligation to update its forward-looking
statements.
Source: Tornier, N.V.